More on Azoline
PRINCETON, N.J., Feb. 18 /PRNewswire-FirstCall/ — Barrier
Therapeutics, Inc. (Nasdaq: BTRX - News), a pharmaceutical company
developing and commercializing products in the field of dermatology,
today announced that it will present five scientific poster
presentations at the American Academy of Dermatology (AAD) 63rd
Annual Meeting being held in New Orleans from February 18-22, 2005.
"Barrier’s strategy is to bring therapeutically significant products
to market in the field of dermatology. The results being presented at
the annual academy meeting discuss recent progress that we have made
in our Azoline and Sebazole(TM) development programs," commented
Geert Cauwenbergh, Ph.D., Chairman and CEO of Barrier Therapeutics.
* Effect of a Single Dose of Azoline (R126638), a New Triazole
Antifungal, in Seborrheic Dermatitis; Poster Number: P1814
* The Activity of Azoline (R126638), a New Triazole Antifungal,
as
Assessed by Corneofungimetry; Poster Number: P1831
* The Irritation Potential of Topical Formulations Containing
Ketoconazole 2% and Desonide 0.05% Alone and in Combination;
Poster Number: P581
* The Contact Sensitization Potential of Topical Formulations
Containing
Ketoconazole 2% and Desonide 0.05% Alone and in Combination;
Poster Number: P580
* A Double-blind, Randomized, Vehicle-controlled, Parellel
Group,
Multicenter Study to Assess The Efficacy and Safety of a
Topical Gel
Product Containing Ketoconazole USP 2% in the Treatment of
Seborrheic
Dermatitis; Poster Number: P1803